Virus inactivation in the 1990s - And into the 21st century: Part 4, culture media, biotechnology products, and vaccines

BioPharm International

Volumn 16, Issue 1, 2003, Pages 50-57

  Sofer, Gail ^a  

^a BioReliance   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZIRIDINE; AZIRIDINE DERIVATIVE; CYTOMEGALOVIRUS VACCINE; DETERGENT; IODINE; OCTANOIC ACID; ORAL POLIOMYELITIS VACCINE; OZONE; POLIOMYELITIS VACCINE; PSORALEN; SURFACTIN;

BIOTECHNOLOGY; HEATING; HYDROSTATIC PRESSURE; IRRADIATION; PASTEURIZATION; REVIEW; VIRUS INACTIVATION; WEST NILE FLAVIVIRUS;

EID: 0037224723     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 1: Skin, Bone, and Cells," BioPharm 15(7), 18-24 (July 2002).
2. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 2: Red Blood Cells and Platelets," BioPharm 15(8), 42-49 (August 2002).
3. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 3a: Plasma and Plasma Products (Heat and Solvent/Detergent Treatments)," BioPharm 15(9), 28-42 (September 2002).
4. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 3b: Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)," BioPharm 15(10), 42-49, 51 (October 2002).
5. Moore, E.C., Keil, D., and Coats, K.S., "Thermal Inactivation of Bovine Immunodeficiency Virus," Appl. Environ. Microbiol. 62(11), 4280-4283, (November 1996).
6. Hilfenhaus, J.W. et al., "Inactivation of HIV-1 and HIV-2 by Various Manufacturing Procedures for Human Plasma Proteins," Cancer Detect. Prev. 14(3), 369-375 (1990).
7. Hilfenhaus, J.W. et al., "Inactivation of Retroviruses in Biologicals Manufactured for Human Use," Dev. Biol. Stand. 75, 159-169 (1991).
8. Willkommen, H., Scheiblauer, H., and Lower, J., "Serum and Serum Substitutes: Virus Safety by Inactivation or Removal," Dev. Biol. Stand. 99, 131-138 (1999).
9. Finka, G. et al., "Evaluation of High Temperature Short Time (HTST) for Use in a Virus Barrier Strategy During Production of Biopharmaceuticals," poster presentation, PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 2001.
10. European Directorate for Quality Medicines, "Pestivirus Contamination of Bovine Sera and Other Bovine Virus Contamination," Proc. Int. Symp., Council of Europe, Paris, 29-30 March 2001.
11. House, C., House, J.A., and Yedloutschnig, R.J., "Inactivation of Viral Agents in Bovine Serum by Gamma Irradiation," Can. J. Microbiol. 36(10), 737-740 (October 1990).
12. Plavsic, Z.M, "Gamma Irradiation of Circoviruses in Fetal Bovine Serum," presented at PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 2001.
13. Preuss, T. et al., "Comparison of Two Different Methods for Inactivation of Viruses in Serum," Clin. Diagn. Lab. Immunol. 4(5), 504-508 (September 1997).
14. Skladanek, M., "Viral Inactivation Utilizing Depth Filter Media Containing a PVPP-Iodine Complex," presented at PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 2001.
15. Carpendale, M.T. and Freeberg, J.K., "Ozone Inactivates HIV at Noncytotoxic Concentrations," Antiviral Res. 16(3), 281-292 (October 1991).
16. Kasermann, F., Wyss, K., and Kempf, C., "Virus Inactivation and Protein Modifications by Ethyleneimines," Antiviral Res. 52(1), 33-41 (2001).
17. Kurth, J. et al., "Efficient Inactivation of Viruses and Mycoplasma in Animal Sera Using UVC Irradiation," Dev. Biol. Stand. 99, 111-118 (1999).
18. Matthews, J.L. et al. "Inactivation of Viruses with Photoactive Compound. Blood Cells," 18(1), 75-88; discussion, 88-89 (1992).
19. North, J., Coombs, R., and Levy, J., "Photodynamic Inactivation of Free and Cell-Associated HIV-1 Using the Photosensitizer, Benzoporphyrin Derivative," J. Acquir. Immune Defic. Syndr. 7(9), 891-898 (September 1994).
20. Vollenbroich, D. et al., "Mechanism of Inactivation of Enveloped Viruses by the Biosurfactant Surfactin from Bacillus Subtilis," Biologicals 25(3), 289-297 (September 1997).
21. Nakagami, T. et al., "Inactivation of Human Immunodeficiency Virus by High Hydrostatic Pressure," Transfusion 36(5), letter, 475-476 (May 1996).
22. Charlebois, T.S. et al., "Viral Safety of B-Domain Deleted Recombinant Factor VIII," Semin. Hematol. 38(2), Suppl. 4, 32-39 (2001).
23. Abujoub, A., Oty, G., and Shepherd, A., "Factors Affecting the Kinetics of Xenotropic Murine Leukemia Virus Inactivation by Low pH: The Role of pH Range, Temperature, Protein Concentration, and Product," presented at PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 2001.
24. Reindel, K., "Generic Approach to Viral Clearance Studies," presented at PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 2001.
25. Xu, Y., "Generic Validation of Virus Removal and Inactivation," presented at PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 2001.
26. Lundblad, J.L. and Seng, R.L., "Inactivation of Lipid-Enveloped Viruses in Proteins by Caprylate," Vox Sang. 60(2), 75-81 (1991).
27. Darling, A., personal Communication, 2000.
28. Lawrence, S.A., "Beta-Propiolactone: Viral Inactivation in Vaccines and Plasma Products," PDA J. Pharm Sci. Technol. 54(3), 209-217 (May-June 2000).
29. Bonafe, C.F. et al, "Virus Inactivation by Anilinonaphthalene Sulfonate Compounds and Comparison with Other Ligands," Biochem. Biophys. Res. Commun. 275(3), 955-961 (7 September 2000).
30. Pontes, L. et al., "Pressure-Induced Formation of Inactive Triple-Shelled Rotavirus Particles Is Associated with Changes in the Spike Protein VP4," J. Mol. Biol. 307(5), 1171-1179 (2001).
31. Jurkiewicz, E. et al., "Inactivation of Simian Immunodeficiency Virus by Hydrostatic Pressure," Proc. Natl. Acad. Sci. USA 18, 92(15), 6935-6937 (July 1995).
32. Rombaut, B. et al., "Thermal Inactivation of Oral Polio Vaccine: Contribution of RNA and Protein Inactivation," J. Virol. 68(10), 6454-6457 (October 1994).
33. Klamm, H., Pollex, G., and Henning, U., "Thermal Inactivation of Different Measles Virus Strains," Acta Virol. 35(2), 200-202 (April 1991).
34. Rueda, P. et al., "Effect of Different Baculovirus Inactivation Procedures on the Integrity and Immunogenicity of Porcine Parvovirus-Like Particles," Vaccine 22,19(7-8), 726-734 (November 2001).
35. Bachmann, M.F. et al., "Formalin Inactivation of Vesicular Stomatitis Virus Impairs T-Cell but not T-Help-Independent B-Cell Responses," J. Virol. 67(7), 3917-3922 (July 1993).
36. Putnak, R. et al., "Development of a Purified, Inactivated, Dengue-2 Virus Vaccine Prototype in Vero Cells: Immunogenicity and Protection in Mice and Rhesus Monkeys," J. Infect. Dis. 174(6), 1176-1184 (December 1996).
37. Cardoso, A.I. et al., "Formaldehyde Inactivation of Measles Virus Abolishes CD46-Dependent Presentation of Nucleoprotein to Murine Class I-Restricted CTLs but not to Class II-Restricted Helper T Cells," Virology 10, 212(1), 255-258 (December 1996).
38. Connors, M. et al., "Pulmonary Histopathology Induced by Respiratory Syncytial Virus (RSV) Challenge of Formalin-Inactivated RSV-Immunized BALB/c Mice Is Abrogated by Depletion of CD4+ T Cells," J. Viral. 66, 7444-7451 (December 1992).
39. Race, E. et al., "A Multistep Procedure for the Chemical Inactivation of Human Immunodeficiency Virus for Use as an Experimental Vaccine," Vaccine 13(16), 1567-1575 (November 1995).
40. Pellegrini, V., "Preparation and Immunogenicity of an Inactivated Hepatitis A Vaccine," Vaccine 11(3), 383-387 (1993).
41. Barteling, S.J. and Vreeswijk, J., "Developments in Foot-and-Mouth Disease Vaccines," Vaccine 9(2), 75-88 (February 1991).
42. Brown, F., "An Overview of the Inactivation of FMDV and the Implications When Residual Virus Is Present in Vaccines," Dev. Biol. Stand. 75, 37-41 (1991).
43. Brown, F., "Review of Accidents Caused by Incomplete Inactivation of Viruses," Dev. Biol. Stand. 81, 103-107 (1993).
44. Hanson, C.V., "Photochemical Inactivation of Viruses with Psoralens: An Overview," Blood Cells 18(1), 7-25 (1992).
45. Groene, W.S. and Shaw, R.D., "Psoralen Preparation of Antigenically Intact Noninfectious Rotavirus Particles," J. Virol. Methods 38(1), 93-102 (July 1992).
46. Bahnemann, M.F., "Inactivation of Viral Antigens for Vaccine Preparation with Particular Reference to the Application of Binary Ethylenimine," Vaccine 8, 299-303 (July 1992).
47. Geoffroy, F. et al., "Inactivation of Human Cytomegalovirus by Sodium Periodate Oxidation," Arch. Virol. 135(1-2), 61-74 (1994).
48. Ogier, G. et al., "Inhibition of Type 5 Adenovirus Infectivity by Periodate Oxidation," Arch. Virol. 135, 43-60 (1994).
49. Andre, F.E., Hepburn, A., and D'Hondt, E., "Inactivated Candidate Vaccines for Hepatitis A," Progr. Med. Virol. 37, 72-95 (1990).
50. Reddish, G.F., Antiseptics, Disinfectants, Fungicides and Chemical and Physical Sterilization, 2nd Ed. (Lea & Febiger, Philadelphia, 1957), pp. 23-29.